Skip to main content
Viromed Medical logo

Viromed Medical — Investor Relations & Filings

Ticker · VMED ISIN · DE000A3MQR65 LEI · 894500XR05MYCVCCR171 DU Manufacturing
Open in API
Filings indexed 45 across all filing types
Latest filing 2026-05-22 Earnings Release
Country DE Germany
Listing DU VMED

About Viromed Medical

https://www.viromed.de/en/

Viromed Medical AG is a medical technology company specializing in the development, manufacture, and distribution of medical products. A pioneer in the field of cold atmospheric plasma (CAP), the company develops devices designed to inactivate harmful viruses, fungi, and bacteria. Its technology has applications in wound healing and is being studied for lung treatments, marketed as a 'digital antibiotic.' Key products include PulmoPlas(R) and plasma care. In addition to its core plasma technology, Viromed develops holistic solutions for infection protection, such as air disinfection, and creates digital platforms to connect healthcare stakeholders. The company serves a network of hospitals, nursing homes, and medical practices.

Recent filings

Filing Released Lang Actions
Viromed Medical AG significantly increases consolidated revenue in the 2025 financial year and achieves a positive net income
Earnings Release Classification · 92% confidence The document is a press release (“Corporate News”) summarizing Viromed Medical AG’s 2025 full-year financial results and noting that the complete annual report has been published online. It provides key revenue and net income highlights but does not contain the full audited financial statements or MD&A typical of an actual annual report (10-K). Therefore, this is an initial announcement of annual financial results (an earnings release), not the full report itself. FY 2025
2026-05-22 English
Viromed Medical AG: Uwe Perbandt, buy
Director's Dealing Classification · 95% confidence The announcement is a public disclosure of transactions by a director (Uwe Perbandt) acquiring company shares, including detailed transaction data (ISIN, volumes, prices, dates). This fits the definition of a Director's Dealing report.
2026-05-18 English
Viromed Medical AG signs exclusive distribution partnership with NEBU-TEC for PulmoPlas with a focus on veterinary applications
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing an exclusive distribution partnership between Viromed Medical AG and NEBU-TEC. It does not contain financial results, regulatory filings like an annual report, management or board changes, dividends, share issues, or other specific filing types. It is a standard corporate news announcement without substantive financial data or meeting materials. Therefore, it falls under the fallback category for general regulatory/corporate announcements (RNS).
2026-05-18 English
Viromed Medical AG: Uwe Perbandt, buy
Director's Dealing Classification · 98% confidence The document is a notification of transactions by a person discharging managerial responsibilities (an insider), detailing the acquisition of shares (price, volume, date, ISIN, etc.). This clearly matches the definition for Director’s Dealing reports.
2026-05-13 English
Viromed Medical AG: ViroCAP med successfully completes regulatory process as a Class IIa medical device starting signal for market launch at the European Wound Congress 2026
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing regulatory approval (Class IIa medical device) and the upcoming market launch. It contains no financial statements, earnings data, or investor presentation materials. It is not a call transcript, management change, dividend notice, or filing of an annual/interim report. It falls under a general regulatory announcement and thus best fits the Regulatory Filings category (RNS).
2026-05-11 English
Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Earnings Release Classification · 95% confidence The document is an ad-hoc announcement dated May 8, 2026, disclosing inside information under Article 17 MAR. It reports preliminary financial results for the 2025 fiscal year, noting that revenue missed forecasts but earnings were positive. It also revises the forecast for 2026 and states that the complete audited financial results for 2025 will be published later on May 22, 2026. The document is short (3879 characters) and serves as a financial update and forecast revision rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It is an earnings update and forecast revision communicated as inside information, fitting best the category of an Earnings Release (ER). FY 2025
2026-05-08 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.